Skip to Content

Moderna Inc MRNA Stock Quote

| Rating as of

Morningstar‘s Stock Analysis MRNA

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Moderna's Vaccine Portfolio Is Advancing, Supporting Our $232 Fair Value Estimate

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Karen Andersen, CFA |

Moderna's mRNA technology has gained rapid validation as sales of its COVID-19 vaccine soared in 2021, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape for innovative vaccines.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MRNA

Company Profile MRNA

Business Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Contact
200 Technology Square
Cambridge, MA, 02139
T +1 617 714-6500
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 2,700

Related Articles MRNA